Kotak Asset Managers invests Rs 20 cr in Cellogen Therapeutics

Kotak Asset Managers invests Rs 20 cr in Cellogen Therapeutics

Mumbai, May 18 (PTI) Kotak Alternate Asset Managers on Monday said it has invested Rs 20 crore in NATCO Pharma-backed Cellogen Therapeutics.The investment has been made through Kotak Life Sciences Fund I (KLSF-I), which typically invests in early- to growth-stage life sciences and healthcare businesses. Cellogen will use the funds to advance its CAR'T clinical programmes, expand its gene therapy pipeline, and strengthen manufacturing, a release …

Kotak Alts invests INR 200 Million in Cellogen Therapeutics

Kotak Alternate Asset Managers Limited (Kotak Alts), through its Kotak Life Sciences Fund I (KLSF-I), which invests in early- to growth-stage life sciences and healthcare businesses, has made an investment of INR 200 million in Cellogen Therapeutics, a biotechnology company focused on cell and gene therapies. The investment will be used to advance Cellogen’s CAR‑T clinical programs, expand its gene therapy pipeline, and strengthen its GMP‑compli…

Biotech Startup Cellogen Therapeutics Raises ₹20 Cr from Kotak Alts

Biotech startup Cellogen Therapeutics has secured ₹20 Cr (about $2 Mn) in funding from Kotak Alternate Asset Managers (Kotak Alts).